GRAIL's Galleri Progresses While Back In Accumulation Levels

Group 1 - GRAIL, Inc. has made significant progress in establishing its Galleri test as a viable alternative for cancer screening since its spin-off from Illumina, Inc. in June 2024 [1] - The Galleri test is capable of screening for over 50 types of cancer, indicating its broad applicability in early detection [1]